All HTA projects in progress or completed are listed below. Published here in the course of each project are the protocol and the HTA report, together with the feedback received from stakeholders. The reports are written in English (with summaries in French, German and Italian).
Long-term treatment with sedative-hypnotic drugs is associated with adverse effects, increased overall mortality and represents a considerable potential for misuse and addiction. The aim of the HTA is to assess the efficacy, safety, cost-effectiveness and budgetary impact of long-term use (> one month) of sedative-hypnotic drugs of the Anatomical Therapeutic Chemical (ATC) categories N05BA (benzodiazepines derivatives in the anxiolytics group), N05CD (benzodiazepine derivatives in the hypnotics and sedatives group), or N05CF (Z-drugs/ benzodiazepine related drugs) listed in the Swiss specialities list in adult patients with primary chronic insomnia disorder.
The Health Technology Assessment (HTA) evaluates the efficacy, safety, cost effectiveness and budgetary impact of monthly treatment with bone-targeted agents compared with trimonthly treatment of patients with bone metastases from solid tumours and multiple myeloma.
The scoping report determines the feasibility of conducting an HTA.
The Health Technology Assessment (HTA) aims to evaluate the safety, efficacy, cost-effectiveness and budgetary impact of treatment with Denosumab (Prolia®) compared to placebo, bisphosphonates and selective oestrogen receptor modulators (SERMs) in patients with osteoporosis.
Some patients after stroke, with multiple sclerosis (MS), or with Parkinson’s disease currently receive physiotherapy over a lengthy period of time (more than 36 physiotherapy sessions per year). The question arises as to whether long-term physiotherapy for these patients has additional benefits compared with those receiving short-term physiotherapy. The aim of the HTA is to assess the efficacy, safety, cost-effectiveness and budgetary impact of long-term physiotherapy for patients after stroke, with MS or Parkinson’s disease. The scoping report showed that no data are currently available for this patient group to conduct an HTA on the efficacy, safety and cost-effectiveness of long-term physiotherapy compared to short-term physiotherapy.
The aim of this HTA short report is to evaluate the efficacy, safety, cost-effectiveness and budget impact of corneal collagen crosslinking (CXL) compared to sham or no treatment in patients with progressive keratoconus.
This report presents a summary of a health technology assessment (HTA) report published by the Canadian Agency for Drugs and Technologies in Health that evaluated the evidence pertaining to the comparative clinical efficacy and safety of six to 12 months dual antiplatelet therapy (DAPT) versus extended DAPT (>12 months), following percutaneous coronary intervention with stent insertion in coronary artery disease patients and various subpopulations.
Infliximab is a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis. In 2016, infliximab was the costliest active substance in Switzerland, generating direct drug costs of over CHF 128 million. For biologics such as infliximab, biosimilars are available, which are sufficiently similar to an approved biological medicinal product (reference product) and are available for a cheaper price. The aim of the HTA is to review the efficacy, safety, cost-effectiveness and budgetary implications of
- treating a patient suffering from rheumatoid arthritis with an infliximab biosimilar instead of the infliximab reference product;
- switching a patient suffering from rheumatoid arthritis from treatment with the infliximab reference product to treatment with an infliximab biosimilar (or vice versa).
The Health Technology Assessment (HTA) intends to review the efficacy, safety, cost-effectiveness and budgetary impact of the use of vitamin D testing in risk groups as defined by the Swiss Federal Nutrition Commission (people with bone disease, older adults, obese individuals, pregnant women, people with dark skin and athletes). It will also analyse evidence regarding the clinical effects of vitamin D supplementation in these risk groups.
The feasibility of a full HTA has been determined on the basis of the scoping report. A full HTA is not justified at this stage, as no clinical studies are available that would enable evaluation of vitamin D tests. This issue could be revisited once such studies are available.
Health Technology Assessment (HTA) is designed to assess the efficacy, safety, cost-effectiveness and budgetary impact of therapy with cannabis as compared with placebo, no therapy or standard of care in patients with various symptoms (pain, spasticity, vomiting and nausea in cancer patients, unintended weight loss).
CDK4/6 inhibitors, such as palbociclib, ribociclib and abemaciclib, are a new class of drugs that are used in combination with endocrine therapy to treat advanced hormone receptor-positive, HER2 receptor-negative breast cancer. Results from clinical trials suggest that some of these new compounds may cause severe side effects. There is also evidence that not all CDK4/6 inhibitors contribute equally to prolonging the survival of burst cancer patients and improving their quality of life. The aim of the health technology assessment (HTA) is therefore to evaluate the efficacy, safety, cost-effectiveness and budgetary impact of treatment with CDK4/6 inhibitors in comparison with each other and with standard therapy.
The aim of the Health Technology Assessment (HTA) is to evaluate the efficacy, safety, cost-effectiveness and budgetary impact of subacromial decompression in patients with subacromial pain.
The aim of the Health Technology Assessment (HTA) is to evaluate the efficacy, safety, cost-effectiveness and budgetary impact of ezetimibe-containing medicines compared to statins or fenofibrate in patients with hypercholesterolaemia or mixed/combined hyperlipidaemia.
The aim of the Health Technology Assessment (HTA) is to evaluate the efficacy, effectiveness, safety, cost-effectiveness and budgetary impact of olmesartan mono- and combination therapies compared to all other sartan mono- and combination therapies available in Switzerland in patients with essential hypertension.
The aim of the HTA is to evaluate the efficacy, safety, cost-effectiveness and budget impact of long-term continuous proton pump inhibitor (PPI) therapy compared to long-term on-demand PPI therapy in patients with non-erosive reflux disease (NERD) and patients with uninvestigated gastroesophageal reflux disease (GERD).
The aim of the short report is to assess the efficacy and safety of glinides and glitazones in treating patients with type 2 diabetes compared to all other non insulin-based antidiabetics available in Switzerland.
The objective of this HTA was to:
- assess the efficacy and safety of both oral and i.v. iron therapy in patients with symptomatic iron deficiency without anaemia in comparison to other therapies or placebo,
- develop insights on specific symptoms and diagnostic markers that make it possible to define an iron deficiency needing treatment and to determine if particular subgroups of patients will benefit more than others from iron therapy,
- assess the cost-effectiveness of oral vs i.v. iron therapy for those indications where a treatment effect is shown.
Scientific evaluation report: Critical appraisal of the Eurofer ans Swissfer study reports (Report in english (05.06.2020) (PDF, 617 kB, 05.06.2020), capital 5 available in german and french (05.06.2020) (PDF, 139 kB, 05.06.2020))
The Health Technology Assessment (HTA) report on statins for the primary prevention of cardiovascular events and mortality in Switzerland. This is done on the basis of the identified number and quality of the primary literature.
Based on the scoping report, the HTA report examines the efficacy, safety, cost-effectiveness and budgetary impact of statin therapy in adults without established cardiovascular disease at low, moderate or (very) high cardiovascular risk compared to no treatment and/or lifestyle adjustment.
The objective of the HTA is to compare the safety and efficacy of chondroitin sulfate with placebo, on-demand analgesics and anti-inflammatory treatments in patients with osteoarthritis of the hands, knees and hips. In addition, the cost-effectiveness and budgetary impact of chondroitin sulfate are to be investigated.
The objective of this HTA is to evaluate the efficacy, safety, cost-effectiveness and budgetary impact of percutaneous vertebroplasty and percutaneous balloon kyphoplasty in patients with symptomatic osteoporotic vertebral compression fractures unresponsive to non-surgical treatment.
- What is the effect of self-measurement of blood glucose on HbA1c in patients with non-insulin-treated diabetes mellitus type 2?
- How does a decrease in HbA1c levels affect clinical outcomes?
- What is the safety profile of self-measurement of blood glucose?
- What is the cost-effectiveness of possible variations in self-measurement of blood glucose?
The aim of the report is:
- to systematically review the evidence on the clinical efficacy and safety of knee arthroscopy for treating degenerative changes in the knee (meniscus and adjacent structures) compared with other, non-invasive forms of therapy
- to assess the cost-effectiveness and calculate the budgetary impact of such procedures
- to review the evidence on clinical efficacy and safety, and to compare the cost-effectiveness and budgetary impact of inpatient versus outpatient knee arthroscopy
Research questions: How does the removal of osteosynthetic material in patients without a medical indication (elective or routine removal) affect complication rates, clinical outcomes, health-related quality of life and cost-effectiveness compared to the retention of osteosynthetic material?
The aim of the report is to systematically review the evidence on the clinical effectiveness and safety of disc prostheses in the cervical and lumbar spine and of interspinous or pedicle-based stabilisation in patients with degenerative changes of the lumbar spine compared to either direct decompression only or fusion.
Last modification 13.07.2021